Pharming Group NV
NASDAQ: PHAR · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Pharming Group NV (PHAR) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $104.37M | $166.72M | $93.40M | $80.07M | $49.59M | $32.01M | $22.28M | $43.37M | $67.75M | $63.06M | $133.34M | $199.38M | $245.45M | $255.91M | $342.55M | $450.44M | $425.80M | $462.85M | $414.18M | $499.81M |
| Cash & equivalents | $34.42M | $74.29M | $27.30M | $22.81M | $13.70M | $4.90M | $6.97M | $23.43M | $41.57M | $34.60M | $33.54M | $70.37M | $91.87M | $74.35M | $167.94M | $217.59M | $207.34M | $61.74M | $56.89M | $146.02M |
| Current assets | $55.97M | $114.75M | $50.08M | $40.93M | $38.90M | $17.06M | $11.17M | $33.97M | $59.76M | $55.86M | $65.41M | $105.87M | $115.44M | $119.44M | $215.47M | $282.80M | $277.50M | $316.34M | $288.32M | $299.38M |
| Total liabilities | $38.59M | $116.14M | $75.96M | $60.99M | $36.16M | $33.55M | $32.40M | $36.45M | $31.46M | $37.00M | $104.45M | $176.82M | $174.81M | $138.53M | $192.39M | $231.73M | $221.16M | $244.07M | $185.27M | $222.79M |
| Current liabilities | $12.13M | $34.33M | $17.47M | $51.97M | $12.88M | $10.54M | $11.86M | $17.85M | $18.09M | $13.47M | $54.03M | $70.22M | $82.60M | $114.25M | $62.91M | $53.02M | $59.70M | $77.97M | $76.42M | $115.79M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | $58.68M | $37.27M | $0.00 | $121.93M | $122.65M | $131.62M | $136.60M | $78.15M | $92.72M |
| Shareholder equity | $65.78M | $50.58M | $17.45M | $19.07M | $14.45M | $-1.54M | $-10.12M | $5.01M | $36.29M | $23.84M | $28.89M | $16.11M | $61.75M | $117.39M | $150.16M | $218.71M | $204.64M | $218.78M | $228.91M | $277.02M |
| Retained earnings | $-238.75M | $-313.88M | $-316.79M | $-375.48M | $-320.80M | $-334.93M | $-263.85M | $-253.24M | $-256.53M | $-263.68M | $-278.96M | $-353.50M | $-331.99M | $-340.71M | $-221.85M | $-309.69M | $-256.43M | $-265.26M | $-285.27M | $-272.90M |
| Accounts receivable | $1.90M | $1.63M | $0.00 | $0.00 | $9.92M | $2.28M | $407139.00 | $638315.00 | $1.32M | $2.11M | $11.97M | $12.22M | $15.34M | $28.86M | $19.25M | $31.28M | $25.33M | $42.62M | $51.95M | $54.69M |
| Inventory | $12.10M | $17.09M | $15.27M | $16.13M | $9.11M | $8.53M | $2.78M | $4.94M | $16.30M | $17.74M | $18.87M | $22.00M | $17.32M | $16.22M | $17.32M | $30.96M | $42.33M | $56.76M | $57.70M | $64.88M |
| Goodwill | $12.13M | $13.40M | $9.74M | $6.18M | — | — | — | — | — | — | — | — | — | — | — | $-87028.00 | — | — | $0.00 | $135.50M |
Frequently asked questions
What is Pharming Group NV's revenue?
Pharming Group NV's trailing twelve-month revenue is $369.49M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is PHAR?
In its most recent fiscal year, PHAR ran a gross margin of 87.90%, an operating margin of 5.13%, and a net margin of 0.76%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does PHAR generate?
PHAR produced $49.31M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is PHAR's balance sheet healthy?
PHAR holds $146.02M in cash and equivalents against $92.72M in long-term debt, on $277.02M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.